Citius Pharmaceuticals (CTXR)
NASDAQ:CTXR

Citius Pharmaceuticals (CTXR) Stock Price & Analysis

1,124 Followers

CTXR Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.77 - $2.01
Previous Close$1.39
Volume1.02M
Average Volume (3M)759.15K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-6.0
Beta1.08
Next EarningsFeb 15, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-0.23
Shares Outstanding146,211,130
R-Squared0.05
Standard Deviation0.28
10 Day Avg. Volume1,449,382
30 Day Avg. Volume759,147
Price to Book (P/B)6.01
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-8.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside183.69% Upside
Rating ConsensusModerate Buy
Alpha-0.00060
Number of Analyst Covering1


Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

CTXR FAQ

What was Citius Pharmaceuticals’s price range in the past 12 months?
Citius Pharmaceuticals lowest stock price was $0.77 and its highest was $2.01 in the past 12 months.
    What is Citius Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Citius Pharmaceuticals’s upcoming earnings report date?
    Citius Pharmaceuticals’s upcoming earnings report date is Feb 15, 2023 which is in 13 days.
      How were Citius Pharmaceuticals’s earnings last quarter?
      Citius Pharmaceuticals released its earnings results on Dec 22, 2022. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.01.
        Is Citius Pharmaceuticals overvalued?
        According to Wall Street analysts Citius Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Citius Pharmaceuticals pay dividends?
          Citius Pharmaceuticals does not currently pay dividends.
          What is Citius Pharmaceuticals’s EPS estimate?
          Citius Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Citius Pharmaceuticals have?
          Citius Pharmaceuticals has 146,211,140 shares outstanding.
            What happened to Citius Pharmaceuticals’s price movement after its last earnings report?
            Citius Pharmaceuticals reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -17.647%.
              Which hedge fund is a major shareholder of Citius Pharmaceuticals?
              Among the largest hedge funds holding Citius Pharmaceuticals’s share is Gotham Asset Management LLC. It holds Citius Pharmaceuticals’s shares valued at 27K.

                ---

                Citius Pharmaceuticals Stock Smart Score

                7
                Neutral
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Positive
                20 days / 200 days
                Momentum
                -2.83%
                12-Months-Change

                Fundamentals

                Return on Equity
                -28.63%
                Trailing 12-Months
                Asset Growth
                -19.96%
                Trailing 12-Months
                The Citius Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Citius Pharmaceuticals

                Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

                ---

                Forecast EPS vs Actual EPS


                Similar Stocks
                Company
                Price & Change
                Follow
                Optinose
                Xeris Pharmaceuticals
                AN2 Therapeutics, Inc.
                Cormedix
                MariMed

                Popular Stocks

                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis